> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-43/
- Published: 2021-06-13T12:00:00.000Z
- Updated: 2026-09-14T17:03:08.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5149531

**Guide on Animal Antimicrobial Drugs**  
6/11/2021 *Federal Register* notice: FDA has made available a final guidance for industry (GFI) #263 entitled *Recommendations for Sponsors of Medically Important Antimicrobial Drugs Approved for Use in Animals to Voluntarily Bring Under Veterinary Oversight All Products That Continue to Be Available as Over-the-Counter.* To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2021-06-11/pdf/2021-12297.pdf?ref=fdaweb.com).

**New Research on Unapproved Use of Approved Drugs**  
*6/11/2021 Federal Register* notice: FDA has submitted to OMB an information collection entitled “Study of Disclosures to Healthcare Providers Regarding Data That Do Not Support Unapproved Use of an Approved Prescription Drug.” The new research is intended to examine physicians’ perceptions and behavioral intentions about an unapproved new use of an approved prescription drug when made aware of other data that are not supportive of the unapproved use. This research will also evaluate the effectiveness of various disclosure approaches for communicating the unsupportive information. FDA says research results should provide a better understanding of physicians’ perceptions of an unapproved use of a prescription drug, and their perceptions about an unapproved use of an approved prescription drug when they are aware of the existence of unsupportive information about it. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2021-06-11/pdf/2021-12265.pdf?ref=fdaweb.com).

**Guide on Patient-reported Outcomes in Cancer Trials**  
*6/10/2021 Federal Register* notice: FDA has made available a draft guidance entitled *Core Patient-Reported Outcomes in Cancer Clinical Trials*. The document provides recommendations to sponsors regarding the collection of a core set of patient-reported clinical outcomes in cancer clinical trials and related considerations for instrument selection and trial design. It focuses on patient-reported outcome measures and is specific to registration trials for anti-cancer therapies intended to demonstrate an effect on survival, tumor response, or delay in the progression of a malignancy. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2021-06-10/pdf/2021-12166.pdf?ref=fdaweb.com).

**Info Collection: Investigational Use Animal Drugs**  
*6/10/2021 Federal Register* notice: FDA has submitted to OMB an information collection extension for “New Animal Drugs for Investigational Use — 21 CFR Part 511 (OMB Control Number 0910–0117).” The collection supports FDA regulations that set forth the conditions for investigational use of new animal drugs and require reporting and recordkeeping. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2021-06-10/pdf/2021-12197.pdf?ref=fdaweb.com).

**Info Collection Extension for Drug GMPs**  
*6/09/2021 Federal Register* notice: FDA has submitted to OMB an information collection extension entitled “Current Good Manufacturing Practice for Finished Pharmaceuticals, Including Medical Gases, and Active Pharmaceutical Ingredients — 21 CFR Parts 210 and 211 and 21 U.S.C 351(a)(2)(B)” (OMB Control Number 0910-0139). The collection supports FDA regulations that govern the manufacture, processing, packing, or holding of finished pharmaceuticals, including medical gases and active pharmaceutical ingredients. FDA says its regulations enable a common understanding of the regulatory process by describing requirements to be followed by drug manufacturers, applicants, and the agency. To view the notice, click [here](https://public-inspection.federalregister.gov/2021-12214.pdf?ref=fdaweb.com).